(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

CHICAGO, April 24 (Reuters) - Thousands of Americans campaigning for the Novavax (NVAX.O), opens new tab COVID-19 booster got some good news this week: the FDA signaled it might still win approval ...

showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's vaccine. This positive announcement aligns with a 17.8% increase in the company's share ...

WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...